MyDrHank vs Oak
Two GLP-1 desks, one scoreboard. We put MyDrHank and Oak head-to-head on the published Brief Score — the same six factors, scored the same way.
MyDrHank
The verdict
MyDrHank takes this head-to-head.
MyDrHank scores 74 to 43 on our six-factor Brief Score — A six-shelf prescription telehealth catalog whose GLP-1 price genuinely holds flat as you titrate — but whose every advertised figure is a twelve-month prepay rate, with the month-to-month price published nowhere.
That doesn't make Oak a bad call — it's best for readers weighing oak specifically who want to know what it does and does not publish before handing over 29 questions' worth of medical history — not readers trying to compare a price today. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| MyDrHank | Oak | |
|---|---|---|
| Brief Score | 74/100 (C) | 43/100 (C) |
| Semaglutide | $259/mo (month-to-month; prepay tiers lower) | $250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning |
| Tirzepatide | $349/mo (month-to-month; prepay tiers lower) | $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning |
| Coverage | 44 states (not KS, LA, MS, NM, ND, WV) | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Newnew to the tracker, no prior reading |
MyDrHank: First reading. The funnel advertises "from $240" tirzepatide and "from $171" semaglutide; both are twelve-month prepay rungs, and the month-to-month rates — $349 and $259 — appear on no page of it.
Oak: Re-read twice on 15 August 2026 with a real browser and no form input, and the figures MOVED BETWEEN THE TWO READS. In the morning its order form showed $200/mo for compounded semaglutide and $250 for tirzepatide; that afternoon, same URL, same entry path, browser storage cleared as a control, it showed $250 and $300 with the strike-throughs gone and every brand line $100 higher. What is stable is WHERE the price is: on the first screen of its order form, before a single question. The tracker previously carried no figure because the ladder was believed to be behind a 29-question intake — it is not, it is in front of it. What remains true is that Oak advertises nine different "starting" prices at once — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — attaches a term to none, and that its headline "$133 / $199" is the three-month prepay under code OAKSAVE200, billed upfront.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.